Navigation Links
Simcere Pharmaceutical Group Announces Collaboration with OSI Pharmaceuticals
Date:10/20/2009

NANJING, China, Oct. 20 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR) ("Simcere" or the "Company"), a leading pharmaceutical company specializing in development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced an agreement with OSI Pharmaceuticals, Inc., to develop, manufacture, and market its KDR/Kit inhibitor OSI-930 in China.

Headquartered in Long Island, OSI is a NASDAQ listed pharmaceutical company specialized in discovery and development of innovative molecular targeted therapies. OSI-930 is an orally active inhibitor of two clinically validated targets: c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2). OSI-930 is designed to target both cancer cell proliferation and blood vessel growth (angiogenesis) in selected tumors. In preclinical studies, OSI-930 shows broad efficacy in tumor models representative of small cell lung cancer, glioblastoma, colorectal, renal, head and neck, non-small cell lung cancer and gastric cancers. The company completed a phase I dose escalation study of OSI-930 in healthy volunteers. A phase I single agent dose escalation study in cancer patients has identified a recommended phase II dose and a phase Ib dose escalation study with erlotinib has also identified a recommended dose for the combination. Both phase I studies in cancer patients have been reported at recent ASCO meetings.

"OSI-930 has potential to help cancer patients, and we are delighted to cooperate with OSI Pharmaceuticals to promote this treatment in China," commented Mr. Jinsheng Ren, Chairman and Chief Executive Officer of Simcere Pharmaceutical Group. "We believe that this is a groundbreaking agreement which will become a model for future R&D cooperation between Chinese and foreign pharmaceutical companies."

'/>"/>
SOURCE Simcere Pharmaceutical Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... HILL, N.C. , Sept. 19, 2014 ... to Best Practices, LLC with three issues he wanted ... , The use of external personnel (especially for secondary ... headcount in the face of increased workload , ... and better knowledge management , How to implement ...
(Date:9/19/2014)... 2014 /PRNewswire-iReach/ -- Market Research Report on ... is a professional and in-depth market survey ... The report firstly reviews the basic information ... and manufacturing technology. The report then explores ... Hydrochloride listing their product specification, capacity, Production ...
(Date:9/19/2014)... 2014 Kiromic, LLC, a Lubbock ... Hance , the former chancellor of Texas Tech University, to ... in July 2014, after raising $1.2 billion for the university. ... Hance , the most successful chancellor in the history of ... as an investor, but also as our new vice chairman ...
Breaking Medicine Technology:In Era of Competing Needs, Market Research Groups Under Pressure to Utilize Automation and External Staffing 2Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 2Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 3Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 4Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 5Former Texas Tech Chancellor Named New Vice Chairman of the Board of Kiromic, LLC 2
... Therapeutics (NYSE Amex: CXM ) today provided an ... Pharmaceuticals, business assets in connection with a proposed asset purchase ... on June 27, 2011, the completion of such an asset ... of the bankruptcy court.  In an effort to expedite the ...
... Corporation,s (NYSE: BSX ) Board of Directors ... up to $1.0 billion of its common stock and ... existing share repurchase program. "This repurchase program ... long-term business prospects, earnings growth potential and our ability ...
Cached Medicine Technology:Cardium Reports on Transdel Transaction 2Cardium Reports on Transdel Transaction 3Cardium Reports on Transdel Transaction 4Boston Scientific Announces $1.0B Share Repurchase Program 2Boston Scientific Announces $1.0B Share Repurchase Program 3
(Date:9/20/2014)... Dallas, TX (PRWEB) September 20, 2014 ... – Forecast and Market Analysis to 2023?. The ... past decade, as it has become saturated with ... (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting ... been facing increasing generic competition. However, the launch ...
(Date:9/20/2014)... Recently, Best Cheap Hosting USA ... its new website. The new site provides the ... products for customers. Here, people can find a ... decision. Also, it has recommended some excellent web ... of the great web hosting suppliers, InMotion ( ...
(Date:9/20/2014)... 20, 2014 "As a nurse, patients always ... said an inventor from Tamaqua, Pa. "The reason that they ... backs of their chairs. My invention enables them to check ... Oxygen Sensor to make it easier to monitor the contents ... knows when the tank is low. It allows changeovers to ...
(Date:9/20/2014)... (PRWEB) September 20, 2014 Earlier this week, ... customers may have had their credit card information pilfered by ... spawning a slew of headline articles like this one ... the only eye opening numbers. , “Most people tend ... almost like it’s a way to score a game,” says ...
(Date:9/20/2014)... Final Cut Pro X Plugin ... the Information theme for FCPX filmmakers. , “Fun, cool, and ... Information theme,” says Christina Austin, CEO of Pixel Film Studios. ... , Information features easy to use controls that give the ... Change the background color, color of each circle outline, the ...
Breaking Medicine News(10 mins):Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 2Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 3Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 4Health News:Best Cheap Hosting USA Launches Its New Website And Recommends InMotion To Worldwide People 2Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 2Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 3Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 4Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 5Health News:Today Pixel Film Studios Announced the Release of the Information Theme for Final Cut Pro X 2
... in Higher Education (AGHE), the educational branch of ... its 35th Annual Meeting and Educational Leadership Conference ... Plaza Hotel-Riverwalk in San Antonio, TX. This conference ... aging to present their work and share ideas about ...
... without spending,a lot of cash? It,s true. In fact, you ... boosting your health, lowering your stress level and,cleaning out your ... Hilling has spent more than 15 years researching,and designing products ... With the ten thrifty tips, this host of "Skin Health ...
... RED BANK, New Jersey, BRUSSELS and MELBOURNE, January 30, ... over a century of expertise, the global leader in ... the web. The,new http://www.ansell.com website is now ... new Investor Centre. , The ...
... Studies Initiated in Other Oncology SettingsLONDON and COPENHAGEN, ... A/S (OMX: GEN) announced today the submission of ... Food and Drug Administration (FDA) for Arzerra(TM) ... leukemia (CLL) is resistant (refractory) to previous therapies. ...
... and LISLE, Ill., Jan. 30 SpineMark Corporation,a ... and,physicians to develop Spine Centers of Excellence, has ... high quality spinal care at,cost effective rates through ... Management solution, the Healthplace Surgery Benefit(TM). As ...
... Management Group, Inc. (Phyhealth) (Pink Sheets: PHYH), ... partnership with physicians and manager of Physhield Insurance ... the following letter to its shareholders:Dear Phyhealth Shareholder:We ... and a new administration in Washington. Healthcare ...
Cached Medicine News:Health News:Teaching about financial crisis among Gerontology Meeting's highlights 2Health News:Ten Thrifty Tips for Radiant Skin 2Health News:Ten Thrifty Tips for Radiant Skin 3Health News:Ansell Limited Launching a New Global Website 2Health News:GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer 2Health News:GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer 3Health News:GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer 4Health News:GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer 5Health News:GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer 6Health News:GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer 7Health News:GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer 8Health News:SpineMark Partners With Healthplace America to Offer Access to Top Quality Spinal Care 2Health News:SpineMark Partners With Healthplace America to Offer Access to Top Quality Spinal Care 3Health News:SpineMark Partners With Healthplace America to Offer Access to Top Quality Spinal Care 4Health News:Phyhealth Provides Update to Shareholders 2Health News:Phyhealth Provides Update to Shareholders 3Health News:Phyhealth Provides Update to Shareholders 4
Knife rasp for shoulder arthroscopy....
Loop handle knot pusher...
Shoulder rasp...
Arthrex has the most extensive offering of arthroscopic suture passing instruments,available anywhere in the world. We have speci? cally designed the function of our,instruments to work hand in hand ...
Medicine Products: